Recently completed Phase I studies testing single-dose escalations of the drug and its food interaction profile indicate that it's safe and well tolerated within the dose range expected for efficacy...The company plans to use net proceeds to support sales, marketing and general administrative activities, clinical research and product development activities and fund working capital and other general corporate purposes

The company expects to begin clinical testing early this year in the U.S., and anticipates a European trial to begin shortly thereafter...The first stage will evaluate the safety and activity of rNAPc2 in a three-tier dose escalation format (2.5, 5 and 10 micrograms/kg

Advaxis Inc., of North Brunswick, N.J., received confirmation that the Gynecologic Oncology Group, a clinical research group of the National Cancer Institute, agreed to conduct and help fund a future Phase II trial of Lovaxin C. The trial is expected to begin following completion of the company's ongoing Phase I/II study, which, to date, has finished enrolling and dosing patients with advanced, recurrent or progressive cervical cancer in the first two of four cohorts...The company is ready to begin

Dynavax Technologies Corp., of Berkeley, Calif., started a Phase I dose-escalation trial with its TLR9 agonist in combination with a standard chemotherapeutic regimen for metastatic colorectal cancer...The 24-week trial will be performed at 36 clinical centers in Canada, Germany and Poland with 500 patients

That single- and multiple-dose escalation study was designed to test the safety, tolerability and pharmacokinetics of the compound vs...and Canaccord Capital Corp.

Dose escalation continues, and the maximum tolerated dose has not been reached at a level of 325 mg twice daily...The trial is enrolling women with confirmed breast cancer and clinical evidence of metastatic disease who are entering their first line of chemotherapy

The company anticipates starting clinical trials late in 2007 or early in 2008...The trial is designed as a dose-escalation study to evaluate the safety and efficacy of that combination

Dose escalation is ongoing, and the primary endpoint is to establish a maximum safe dose...The double-blind, dose-escalation study is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the next-generation interferon alpha for hepatitis C virus

The compound initially will be evaluated in dose-escalation studies in healthy volunteers for safety, exposure and inhibition of mechanism-related biomarkers...and oral formulations in clinical development, the company said

Forest Laboratories Inc.,, of New York, and Paion AG, of Aachen, Germany, said the independent data safety monitoring committee lifted the clinical hold on its stroke drug, desmoteplase, which is being studied in the DIAS-2 Phase IIb/III trial, following a review of cumulative data from 170 randomized subjects...Assuming the successful completion of additional preclinical tests and the trial, the company expects to pursue further clinical studies, including a multiple-dose Phase I trial in healthy

The results will serve as the foundation for multiple Phase II clinical trials involving acute inflammation...The open-label study will test the vaccine in a dose-escalation trial involving 24 healthy volunteers

The 36-patient trial will involve an initial dose-escalation segment in combination with conventional fractionated radiotherapy and cisplatin...Peregrine Pharmaceuticals Inc., of Tustin, Calif., completed enrollment ahead of schedule in a Phase Ib dose-escalation study of bavituximab, an anti-phosphatidylserine immunotherapeutic monoclonal antibody for chronic hepatitis C virus

AnorMED Inc., of Vancouver, British Columbia, completed enrollment in the second pivotal Phase III clinical trial evaluating its proprietary product Mozobil in cancer patients, and said it is on track to meet its schedule of releasing top-line data from both Phase III trials in the first half of 2007...The open-label, sequential, dose-escalation study will be conducted at several cancer institutions to examine the safety, tolerability and optimal dosing of AV-412

The product inhibited production of IL-1-beta and TNF-alpha after ex-vivo stimulation of clinical samples...The study is being conducted in collaboration with the Huntington Study Group and includes two parts: a dose-escalation phase to determine the optimal doses of Dimebon, followed by a three-month randomized, placebo-controlled phase to evaluate the drug's safety and preliminary efficacy in about 75 patients

The Phase I dose-escalation part of the study, which is expected to enroll about 25 patients with hepatocellular cancer, is intended to establish dosing safety and the combination's schedule in that patient population...Nitec Pharma AG, of Basel, Switzerland, said it saw positive results in a Phase III clinical trial with Lodotra, a new, modified-release tablet that has been developed to optimize the efficacy of orally administered low-dose prednisone in rheumatoid arthritis

InterMune Inc., of Brisbane, Calif., applied to begin clinical trials of ITMN-191, an orally available hepatitis C virus protease inhibitor, in France...The trial is a Phase I/IIa, open-label, dose escalation study to evaluate VQD-001 in combination with interferon alpha-2b for patients with advanced malignancies

The double-blind, placebo-controlled, dose-escalation study includes healthy male and female volunteers...Neuren will provide the drug product, as well as access to preclinical, clinical and regulatory documents related to Glypromate

It is an open-label, dose-escalation study that aims to establish the maximum tolerated dose and safety profile of PXD101...Clinical trial site initiations and the enrollment of women for the trial began in late July, when the company announced it would submit applications to the FDA for the products: a screening test to detect the presence of 14 high-risk types of HPV and a genotyping test to detect two specific types of HPV-16 and 18, which cause about 70 percent of the cases of cervical cancer

Oncolytics Biotech Inc., of Calgary, Alberta, began patient enrollment in its clinical trial of Reolysin to treat patients with recurrent malignant gliomas...The trial is an open-label, dose-escalation Phase I/II study in which a single dose of Reolysin is administered by infusion to patients with recurrent malignant gliomas that are refractory to standard therapy